Literature DB >> 21110190

Binding of [123I]iodobenzamide to the rat D2 receptor after challenge with various doses of methylphenidate: an in vivo imaging study with dedicated small animal SPECT.

Susanne Nikolaus1, Christina Antke, Markus Beu, Konstantin Kley, Andreas Wirrwar, Joseph P Huston, Hans-Wilhelm Müller.   

Abstract

PURPOSE: The effect of various doses of methylphenidate on the binding of [(123)I]iodobenzamide ([(123)I]IBZM) to the rat D(2) receptor was assessed using small animal SPECT.
METHODS: D(2) receptor binding was measured at baseline and after pretreatment with various doses of methylphenidate. For baseline and methylphenidate challenge, striatal equilibrium ratios (V(3)″) were computed as an estimation of the binding potential.
RESULTS: After methylphenidate, striatal V(3)″ was 1.61 ± 0.61 (mean ± SD; 0.3 mg/kg), 0.91 ± 0.44 (3 mg/kg), 1.01 ± 0.44 (10 mg/kg), 0.91 ± 0.34 (30 mg/kg) and 0.99 ± 0.51 (60 mg/kg). Baseline values amounted to 1.73 ± 0.48, 1.32 ± 0.35, 1.50 ± 0.27, 1.82 ± 0.55 and 1.66 ± 0.41, respectively. Differences between baseline and methylphenidate were significant for the doses 3, 10, 30 and 60 mg/kg, whereas no significant difference was obtained for 0.3 mg/kg methylphenidate. Between-group differences of percentage reduction of D(2) receptor binding were only significant for the groups pretreated with 0.3 and 30 mg/kg methylphenidate, respectively.
CONCLUSION: Methylphenidate between 0.3 and 60 mg/kg decreased D(2) receptor binding with a maximum reduction after 30 mg/kg. As no between-group differences were evident between the groups pretreated with 3, 10, 30 and 60 mg/kg, it may be inferred that doses ≥ 3 mg/kg were sufficient to induce maximum dopamine concentration in the synaptic cleft. Further investigations are needed in order to clarify whether the variation between subjects can be accounted for by different synaptic mechanisms at the presynaptic binding site.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21110190     DOI: 10.1007/s00259-010-1668-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  33 in total

1.  Quantitative analysis of dopamine D2 receptor kinetics with small animal positron emission tomography.

Authors:  Susanne Nikolaus; Markus Beu; Henning Vosberg; Hans-Wilhelm Müller; Rolf Larisch
Journal:  Methods Enzymol       Date:  2004       Impact factor: 1.600

Review 2.  Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans.

Authors:  Susanne Nikolaus; Christina Antke; Konstantin Kley; Thorsten D Poeppel; Hubertus Hautzel; Daniela Schmidt; Hans-Wilhelm Müller
Journal:  Rev Neurosci       Date:  2007       Impact factor: 4.353

3.  [123I]Iodobenzamide binding to the rat dopamine D2 receptor in competition with haloperidol and endogenous dopamine--an in vivo imaging study with a dedicated small animal SPECT.

Authors:  Susanne Nikolaus; Rolf Larisch; Andreas Wirrwar; Marlyse Jamdjeu-Nouné; Christina Antke; Markus Beu; Nils Schramm; Hans-Wilhelm Müller
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07-08       Impact factor: 9.236

4.  Preparation and biodistribution of [125I]IBZM: a potential CNS D-2 dopamine receptor imaging agent.

Authors:  H F Kung; Y Z Guo; J Billings; X Xu; R H Mach; M Blau; R E Ackerhalt
Journal:  Int J Rad Appl Instrum B       Date:  1988

5.  [TierSPECT: performance of a dedicated small-animal-SPECT camera and first in vivo measurements].

Authors:  Andreas K Wirrwar; Susanne Nikolaus; Nils U Schramm; Shahram Arkian; Mathias Cohnen; Hans-Wilhelm Müller
Journal:  Z Med Phys       Date:  2005       Impact factor: 4.820

Review 6.  Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders--results from in vivo imaging studies.

Authors:  Susanne Nikolaus; Christina Antke; Markus Beu; Hans-Wilhelm Müller
Journal:  Rev Neurosci       Date:  2010       Impact factor: 4.353

7.  Methylphenidate-induced alterations in synaptic vesicle trafficking and activity.

Authors:  Trent J Volz; Sarah J Farnsworth; Glen R Hanson; Annette E Fleckenstein
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

8.  Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain.

Authors:  N D Volkow; G Wang; J S Fowler; J Logan; M Gerasimov; L Maynard; Y Ding; S J Gatley; A Gifford; D Franceschi
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

9.  Dynamic SPECT imaging of dopamine D2 receptors in human subjects with iodine-123-IBZM.

Authors:  J P Seibyl; S W Woods; S S Zoghbi; R M Baldwin; H M Dey; A W Goddard; Y Zea-Ponce; G Zubal; M Germine; E O Smith
Journal:  J Nucl Med       Date:  1992-11       Impact factor: 10.057

Review 10.  In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders.

Authors:  Susanne Nikolaus; Christina Antke; Hans-Wilhelm Müller
Journal:  Behav Brain Res       Date:  2009-06-10       Impact factor: 3.332

View more
  4 in total

Review 1.  The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.

Authors:  Stephen V Faraone
Journal:  Neurosci Biobehav Rev       Date:  2018-02-08       Impact factor: 8.989

2.  Relationship between L-DOPA-induced reduction in motor and exploratory activity and degree of DAT binding in the rat.

Authors:  Susanne Nikolaus; Markus Beu; Angelica Maria De Souza Silva; Joseph P Huston; Hubertus Hautzel; Owen Y Chao; Christina Antke; Hans-Wilhelm Müller
Journal:  Front Behav Neurosci       Date:  2014-12-17       Impact factor: 3.558

3.  Effects of L-DOPA on striatal iodine-123-FP-CIT binding and behavioral parameters in the rat.

Authors:  Susanne Nikolaus; Markus Beu; Hubertus Hautzel; Angelica M De Souza Silva; Christina Antke; Andreas Wirrwar; Joseph P Huston; Hans-Wilhelm Müller
Journal:  Nucl Med Commun       Date:  2013-12       Impact factor: 1.690

Review 4.  The role of preclinical SPECT in oncological and neurological research in combination with either CT or MRI.

Authors:  Monique R Bernsen; Pieter E B Vaissier; Roel Van Holen; Jan Booij; Freek J Beekman; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05       Impact factor: 9.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.